BFEC
CORT icon

Benjamin F. Edwards & Company’s Corcept Therapeutics CORT Stock Holding History

Benjamin F. Edwards & Company’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-234
Closed -$8K – 2133
2023
Q4 		$8K Buy
+234
New +$6.42K ﹤0.01% 1712
2021
Q4 		– Sell
-80
Closed -$2K – 1711
2021
Q3 		$2K Buy
+80
New +$1.67K ﹤0.01% 1621

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Benjamin F. Edwards & Company's CORT Position: Q1 2024 in Review

Benjamin F. Edwards & Company sold out of Corcept Therapeutics (CORT) in Q1 2024, closing a stake of 234 shares — an estimated $8K sold.

Benjamin F. Edwards & Company first reported a position in CORT in Q3 2021 and held it in 2 quarters. The position peaked at $8K in Q4 2023. 287 funds tracked by Wall St. Rank hold CORT as of Q1 2024.

  • Benjamin F. Edwards & Company reported no remaining Corcept Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 234 Corcept Therapeutics shares in Q1 2024, an estimated $8K.
  • Benjamin F. Edwards & Company first reported a position in Corcept Therapeutics in Q3 2021 and held it in 2 quarters.
  • Benjamin F. Edwards & Company's Corcept Therapeutics position peaked at $8K in Q4 2023.
  • 287 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q1 2024, filed 29 Apr 2024.